US2016000733A1PendingUtilityA1

Nmda receptor antagonist formulation with reduced neurotoxicity

45
Individually held — no corporate assignee on recordPriority: Sep 25, 2002Filed: Mar 23, 2015Published: Jan 7, 2016
Est. expirySep 25, 2022(expired)· nominal 20-yr term from priority
Inventors:Fred H. MermelsteinRandi Albin
A61P 29/02A61P 29/00A61K 31/137A61K 9/0043A61K 31/135A61K 31/14A61K 9/0019A61K 9/08A61K 47/02
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device comprises a pharmaceutical composition comprising an aqueous solution containing about 10% ketamine hydrochloride and about 0.001% to about 0.2% benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered. 
     
     
         2 . The spray device of  claim 1 , wherein the pharmaceutical composition further comprises a suitable carrier selected from the group consisting of water, saline, bicarbonate, sucrose and mixtures thereof. 
     
     
         3 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device comprises a pharmaceutical composition comprising an aqueous solution containing about 10% ketamine hydrochloride and about 0.002% benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered. 
     
     
         4 . A spray device for intranasal delivery of a pharmaceutical composition, wherein the spray device comprises a pharmaceutical composition comprising an aqueous solution containing about 0.01 mg/kg to about 1 mg/kg ketamine hydrochloride and about 0.001% to about 0.2% per unit dose benzalkonium chloride, wherein the composition does not cause any significant neurotoxicity, and wherein the level of neurotoxicity is comparable to sterile water when administered. 
     
     
         5 . The spray device of  claim 4 , wherein the pharmaceutical composition further comprises a suitable carrier selected from the group consisting of water, saline, bicarbonate, sucrose and mixtures thereof. 
     
     
         6 . The spray device of  claim 4 , wherein the pharmaceutical composition is administered nasally with 1 to 5 sprays of the device. 
     
     
         7 . The spray device of  claim 6 , wherein the pharmaceutical composition is administered nasally with 2 sprays of the device.

Join the waitlist — get patent alerts

Track US2016000733A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.